Is Zai Lab Limited (ZLAB) a Buy, Sell, or Hold?
Zai Lab Limited
NASDAQ:ZLAB
$19.3 USD
-$0.32 (-1.63%)
- Volume
- 491.21K
- Average Volume
- 902.05K
- Market Capitalization
- $2.18B
- P/E Ratio
- -12.07
- Dividend Yield
- 0.00%
- Price Target
- $52.50
- Year High
- $41.20
- Year Low
- $15.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.40
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ying Du |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ZLAB |
| CUSIP | 98887Q104 |
| CIK | 0001704292 |
| Web | https://www.zailaboratory.com |
| Phone | 86 21 6163 2588 |
| Currency | USD |
| Employees | 1784 |
| Country | CN |
Liquidity
| Debt-to-Equity Ratio | 0.35 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.40 |
| Quick Ratio | 2.19 |
| Cash Ratio | 1.91 |
Sales & Book Value
| Annual Sales | $460.16M |
| Price / Sales | 4.94 |
| Cash Flow | -0.09 |
| Price / Cash Flow | -21.31 |
| Price / Book | 3.32 |
Price Target and Rating
| Average Stock Price Forecast | $52.50 |
| High Stock Price Forecast | $75.00 |
| Low Stock Price Forecast | $35.00 |
| Forecast Upside/Downside | -63.24% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.6 |
| Trailing P/E Ratio | -12.07 |
| PEG Ratio | -0.06 |
| P/E Growth | -0.06 |
| Net Income | $-175.54M |
| Net Margin | -39.29% |
| Pretax Margin | -39.62% |
| Return on Equity | -24.29% |
| Return on Assets | -16.23% |
Financials Score
| AltmanZ Score | 0.16 |
| Piotroski Score | 2.00 |
| Working Capital | 551.75M |
| Total Assets | 1.1B |
| Ebit | -173.94M |
| Market Cap | 2.24B |
| Total Liabilities | 433.76M |
Poll Results
About Zai Lab Limited (NASDAQ:ZLAB) Stock
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odron ... extamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
2026-06-16 07:00:00
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of pulmonary neuroendocrine carcinomas (NECs). The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Pro.
2026-06-08 20:34:00
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial, wh.
Zai Lab Announces Changes to Senior Leadership Team
2026-05-21 18:09:00
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,".
Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
2026-05-13 09:57:20
Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues, shifting focus to global pipeline assets. I assign zero intrinsic value to ZLAB's China business, given minimal "bottom line" contributions from blockbuster launches like Vyvgart and anticipated similar outcomes for KarXT. Zoci, a wholly owned Phase 3 oncology asset, is the key value driver for the company, with a modeled global rNPV near $1 billion and potential for multi-billion upside if expanded to 1L SCLC.
2026-05-11 07:00:00
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) following progression after standard first-line therapy. epNECs are an aggressive mal.
Zai Lab Q1 Earnings Call Highlights
2026-05-09 05:07:41
Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and immunology pipeline and pointed to multiple upcoming regulatory and clinical milestones.
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
2026-05-07 22:41:14
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
2026-05-07 10:31:12
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Frequently Asked Questions
-
What is the current Zai Lab Limited (ZLAB) stock price?
-
Zai Lab Limited(NASDAQ:ZLAB) stock price is $19.3 in the last trading session. During the trading session, ZLAB stock reached the peak price of $41.2 while $15.96 was the lowest point it dropped to. The percentage change in ZLAB stock occurred in the recent session was --1.63% while the dollar amount for the price change in ZLAB stock was -$-0.32.
-
ZLAB's industry and sector of operation?
-
The NASDAQ listed ZLAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ZLAB?
-
Christine Chiou | Senior Vice President & Head of Investor Relations
James Yan DABT | Chief Operating Officer of Global R&D
Rafael G. Amado | President and Head of Global Research & Development
Shan He | Senior Vice President & Chief Business Officer
Ying Du | Founder, Chairperson & Chief Executive Officer -
How many employees does ZLAB have?
-
Number of ZLAB employees currently stands at 1784. ZLAB operates from Jinchuang Plaza, Shanghai, None 201210, CN.
-
Link for ZLAB official website?
-
Official Website of ZLAB is: https://www.zailaboratory.com
-
How do I contact ZLAB?
-
ZLAB could be contacted at phone #86 21 6163 2588 and can also be accessed through its website. ZLAB operates from Jinchuang Plaza, Shanghai, None 201210, CN.
-
How many shares of ZLAB are traded daily?
-
The average number of ZLAB shares traded daily for last 3 months was 902.05K.
-
What is the market cap of ZLAB currently?
-
The market value of ZLAB currently stands at $2.18B with its latest stock price at $19.3